Drug intelligence / Profile preview

QGUM-01

Development stage: Preclinical
Lead developer: AceMapAI Biotechnology

Overview

QGUM-01 is a preclinical drug candidate currently under development by AceMapAI Biotechnology (also operating as QureGenAI). As of 2024, the program is classified as "PCC Ready" (Preclinical Candidate Ready), indicating that a lead molecule has been identified and is prepared for IND-enabling studies. AceMapAI Biotechnology utilizes an artificial intelligence-driven platform for drug discovery; however, specific details regarding the molecular modality, biological target, and intended therapeutic indications for QGUM-01 have not yet been publicly disclosed by the company.

Beyond the preview

Go deeper on QGUM-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QGUM-01.

Explore the full profile